Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$107,939 Mln
P/E Ratio
25.66
P/B Ratio
2.19
Industry P/E
87.38
Debt to Equity
0.48
ROE
0.08 %
ROCE
4.83 %
Div. Yield
3.32 %
Book Value
--
EPS
--
CFO
$62,337.00 Mln
EBITDA
$87,217.00 Mln
Net Profit
$38,845.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| 4.39 | -6.28 | -9.81 | 4.58 | -7.87 | -3.71 | 0.90 |
|
BSE Sensex
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P 100
| -8.75 | -3.78 | -9.47 | 9.72 | 11.73 | 14.98 | 11.11 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| -3.01 | 6.00 | -24.87 | -9.79 | 5.70 | 27.34 | 15.10 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 105.62 | 30,300.75 | 24.38 | 21.11 | |
| 80.84 | 16,512.40 | 39.08 | 5.18 | |
| 31.33 | 2,771.88 | 20.48 | 14.33 | |
| 224.42 | 37,019.85 | 52.55 | 13.63 |
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter... defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland. Read more
Chairman of the Board & CEO
Mr. Geoffrey Straub Martha
Executive VP & CFO
Ms. Karen L. Parkhill
Headquarters
Galway
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Medtronic PLC (MDT) stood at $ 101,813 Mln as on 31-Jan-25
The share price of Medtronic PLC (MDT) is $83.39 (NYSE) as of 28-Apr-2025 13:36 EDT. Medtronic PLC (MDT) has given a return of -7.87% in the last 3 years.
Medtronic PLC (MDT) has a market capitalisation of $ 107,939 Mln as on 25-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Medtronic PLC (MDT) is 2.19 times as on 25-Apr-2025, a 39% discount to its peers’ median range of 3.59 times.
The P/E ratio of Medtronic PLC (MDT) is 25.66 times as on 25-Apr-2025, a 71% discount to its peers’ median range of 87.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Medtronic PLC (MDT) and enter the required number of quantities and click on buy to purchase the shares of Medtronic PLC (MDT).
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
The CEO & director of Mr. Geoffrey Straub Martha. is Medtronic PLC (MDT), and CFO & Sr. VP is Ms. Karen L. Parkhill.
There is no promoter pledging in Medtronic PLC (MDT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
3,588
|
|
|
2,994
|
|
|
1,616
|
|
|
277
|
| Medtronic PLC (MDT) | Ratios |
|---|---|
|
Return on equity(%)
|
8.69
|
|
Operating margin(%)
|
20.23
|
|
Net Margin(%)
|
12.83
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Medtronic PLC (MDT) was $0 Mln.
$-0.77
(
